Mode
Text Size
Log in / Sign up

Long COVID prevalence is 30.8% among individuals with confirmed or probable SARS-CoV-2 infectionAnalysis Shows High Prevalence of Long COVID After Infection

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that Long COVID prevalence is 30.8%, but high heterogeneity limits its use as a precise global rate.

This systematic review and meta-analysis synthesized data from 22 studies involving more than 200,000 participants to determine the prevalence of Long COVID and post-COVID-19 condition (PCC). The study focused on individuals with confirmed or probable SARS-CoV-2 infection at least 4 weeks after acute infection.

The analysis found an overall pooled prevalence of 30.8% (95% CI 26.8-35.0). Prevalence varied significantly based on clinical setting and definition: hospitalized cohorts showed a higher prevalence of 37.9% (95% CI 29.5-47.1), while non-hospitalized or community-based cohorts showed 26.2% (95% CI 22.0-30.9). Furthermore, the use of broader symptom-based definitions resulted in a higher prevalence of 39.7% (95% CI 30.5-49.5) compared to the WHO-defined PCC, which showed 22.8% (95% CI 14.3-34.4).

The authors noted extreme heterogeneity (I2 = 99.7%) and variations in terminology and operational definitions as primary limitations. Due to this high heterogeneity, the pooled prevalence figures should be interpreted as descriptive summaries rather than a single precise global rate. These findings highlight the substantial public health burden of Long COVID/PCC.

How this fits prior evidence

This meta-analysis addresses a gap in quantifying the scale of post-acute conditions following SARS-CoV-2 infection. It extends prior evidence regarding increased post-acute risks after SARS-CoV-2 versus other respiratory viral infections by providing specific prevalence rates for Long COVID and PCC. While previous reviews focused on mechanisms like post-exertional malaise or pediatric presentations, this study provides a large-scale quantification of the condition's prevalence in both hospitalized and community settings.

Researchers analyzed data from over 200,000 people to determine how common Long COVID is following a SARS-CoV-2 infection. The study looked at patients who were monitored for at least four weeks after their initial illness. They found that approximately 30.8 percent of the total group experienced symptoms consistent with Long COVID.

The data showed that the risk may be higher for some groups. Specifically, people who were hospitalized during their initial infection had a higher rate of Long COVID, at about 37.9 percent. In contrast, those not hospitalized had a lower reported prevalence of around 26.2 percent.

Because different studies used different ways to define the condition, the results can vary. Some definitions led to a 22.8 percent rate, while broader symptom-based definitions showed nearly 40 percent. Because these findings come from many different types of studies, the numbers should be seen as a general summary rather than a precise global rate.

What this means for you:
About 31% of people experience Long COVID, with higher rates reported among those who were hospitalized.

Common questions

How common is Long COVID?

The study found an overall prevalence of 30.8 percent for Long COVID among the participants. However, because different studies used different definitions to identify the condition, this number serves as a general summary rather than one precise rate.

Does being hospitalized increase the risk of Long COVID?

The data suggests that hospitalization is linked to higher rates. The study found a 37.9 percent prevalence in hospitalized groups, compared to 26.2 percent in non-hospitalized or community-based cohorts.

Why do the reported percentages vary so much?

The numbers vary because different studies used different definitions for what counts as Long COVID. Using a specific World Health Organization definition resulted in 22.8 percent, while broader symptom-based definitions showed a higher rate of 39.7 percent.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
BackgroundLong COVID is an umbrella term for persistent, relapsing, or newly developed health problems after SARS-CoV-2 infection, whereas post-COVID-19 condition (PCC) refers more specifically to the World Health Organization clinical case definition. Reported prevalence varies substantially because of differences in terminology, operational definitions, study populations, follow-up duration, hospitalization status, and symptom ascertainment. This systematic review and meta-analysis synthesized global observational evidence on Long COVID/PCC prevalence and examined major sources of variability.MethodsA systematic review and meta-analysis was conducted according to PRISMA 2020 principles. PubMed/MEDLINE, Scopus, Web of Science, and the WHO COVID-19 Global Literature Database were searched for studies published from 1 January 2020 to 23 February 2026. Observational studies were eligible if they included individuals with confirmed or probable SARS-CoV-2 infection, reported Long COVID/PCC or persistent post-COVID symptoms at least 4 weeks after acute infection, and provided numerator and denominator data. Terminology and operational case definitions were extracted separately. Prevalence estimates were pooled using a random-effects model with logit transformation and back-transformation. Heterogeneity was assessed using Cochran's Q, I2, tau2, and prediction intervals. Subgroup and sensitivity analyses were performed.ResultsTwenty-two studies contributing 27 prevalence estimates and more than 200,000 participants were included. The primary estimate-level pooled prevalence was 30.8% (95% CI 26.8–35.0). Heterogeneity was extreme: Q = 8031.9, df = 26, p < 0.001; I2 = 99.7%; tau2 = 0.252 on the logit scale. The prediction interval was 14.0–54.8%. Pooled prevalence was higher among hospitalized cohorts (37.9%, 95% CI 29.5–47.1) than among non-hospitalized, community-based, or mixed cohorts (26.2%, 95% CI 22.0–30.9). WHO-defined PCC yielded lower prevalence (22.8%, 95% CI 14.3–34.4) than broader symptom-based definitions (39.7%, 95% CI 30.5–49.5). Cohort-level sensitivity analysis yielded a similar prevalence of 31.0% (95% CI 26.8–35.4).ConclusionLong COVID/PCC represents a substantial post-acute public health burden. However, because heterogeneity was extreme, the pooled prevalence should be interpreted as a descriptive summary of heterogeneous observational evidence rather than as a single precise global rate. Standardized definitions, harmonized surveillance, transparent reporting, rehabilitation pathways, and multidisciplinary care models are needed.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.